Publications
Strober B, van de Kerkhof PCM, Callis Duffin K, Poulin Y, Warren RB, de la Cruz C, van der Walt JM, Stolshek BS, Martin ML, de Carvalho AVE. Feasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis Council. Am J Clin Dermatol. 2019 Oct;20(5):699-709. doi: 10.1007/s40257-019-00458-2.
Viswanathan HN, Mutebi A, Milmont CE, Gordon K, Wilson H, Zhang H, Klekotka PA, Revicki DA, Augustin M, Kricorian G, Nirula A, Strober B. Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis. Value Health. 2017 Sep;20(8):1174-1179. doi: 10.1016/j.jval.2016.11.020. Epub 2017 Jun 16.
Kimball AB, Naegeli AN, Edson-Heredia E, Lin CY, Gaich C, Nikai E, Wyrwich K, Yosipovitch G. Psychometric Properties of the Itch Numeric Rating Scale in Patients with Moderate-to-Severe Plaque Psoriasis. Br J Dermatol. 2016 Jul;175(1):157-62. doi: 10.1111/bjd.14464. Epub 2016 May 8.
Wilson HD, Mutebi A, Revicki DA, Mease PJ, Genovese MC, Erondu N, Nirula A, Feng JY, Viswanathan HN. Reliability and Validity of the Psoriasis Symptom Inventory in Patients with Psoriatic Arthritis. Arthritis Care Res (Hoboken). 2015 Dec;67(12):1750-6. doi: 10.1002/acr.22653.
Feldman SR, Bushnell DM, Klekotka PA, Scanlon M, Martin ML, Wade SW, Yang W, Pinto L, Kircik L, Viswanathan HN. Differences in Psoriasis Signs and Symptom Severity between Patients with Clear and Almost Clear Skin in Clinical Practice. J Dermatolog Treat. 2016;27(3):224-7. doi: 10.3109/09546634.2015.1093589. Epub 2015 Oct 7.
Martin ML, Gordon K, Pinto L, Bushnell DM, Chau D, Viswanathan HN. The Experience of Pain and Redness in Patients with Moderate to Severe Plaque Psoriasis. J Dermatolog Treat. 2015 Oct;26(5):401-5. doi: 10.3109/09546634.2014.996514. Epub 2015 Sep 4.
Viswanathan HN, Chau D, Milmont CE, Yang W, Erondu N, Revicki DA, Klekotka P. Total Skin Clearance Results in Improvements in Health-related Quality of Life and Reduced Symptom Severity among Patients with Moderate to Severe Psoriasis. J Dermatolog Treat. 2015 Jun;26(3):235-9. doi: 10.3109/09546634.2014.943687. Epub 2014 Jul 31.
Gordon KB, Kimball AB, Chau D, Viswanathan HN, Li J, Revicki DA, Kricorian G, Ortmeier BG. Impact of Brodalumab Treatment on Psoriasis Symptoms and Health-related Quality of Life: Use of a Novel Patient-reported Outcome Measure, the Psoriasis Symptom Inventory. Br J Dermatol. 2014 Mar; 170(3):705-715.
Bushnell DM, Martin ML, Scanlon M, Chen T, Chau D, Viswanathan HN. Equivalence and Measurement Properties of an Electronic Version of the Psoriasis Symptom Inventory. Qual Life Res. 2014 Apr;23(3):897-906. doi: 10.1007/s11136-013-0527-1. Epub 2013 Sep 20.
Revicki DA, Jin Y, Wilson HD, Chau D, Viswanathan HN. Reliability and Validity of the Psoriasis Symptom Inventory in Patients with Moderate-to-Severe Psoriasis. J Dermatolog Treat. 2014 Feb; 25(1):8-14. [Epub 2013 Jun 11]
Bushnell DM, Martin ML, McCarrier K, Gordon K, Chiou CF, Huang X, Ortmeier B, Kricorian G. Validation of the Psoriasis Symptom Inventory (PSI), a Patient-Reported Outcome Measure to Assess Psoriasis Symptom Severity. J Dermatolog Treat. 2013 Oct;24(5):356-60. doi: 10.3109/09546634.2012.742950. Epub 2012 Dec 8.
Martin ML, McCarrier KP, Chiou CF, Gordon K, Kimball AB, Van Voorhees AS, Gottlieb AB, Huang X, Globe D, Chau D, Viswanathan HN, Kricorian G. Early Development and Qualitative Evidence of Content Validity for the Psoriasis Symptom Inventory (PSI), a Patient-Reported Outcome Measure of Psoriasis Symptom Severity. J Dermatolog Treat. 2013 Aug;24(4):255-60. doi: 10.3109/09546634.2012.759639.
Presentations
Bushnell D, Viswanathan H., Martin M, Wade S, Scanlon M, Yang W, Pinto L, Kircik L, Klekotka P. Differences in Patient Reported Psoriasis Symptom Severity Between Patients Rated as “Clear” Versus “Almost Clear” Based on Physician Global Assessment. AAD, San Francisco, 2015.
Bushnell D, Viswanathan H., Martin M, Wade S, Scanlon M, Yang W, Pinto L, Kircik L, Klekotka P.Differences in Patient Reported Psoriasis Symptom Severity Between Patients Rated as “Clear” Versus “Almost Clear” Based on Physician Global Assessment. IFPA, Stockholm, 2015.
Martin M, Chau D, McCarrier K, Ascoytia C, Viswanathan H. How do Patients with Chronic Plaque Psoriasis Describe the Color of their Skin Lesions Across Fitzpatrick Skin Types? Presented at FCD, Las Vegas, 2014.
Martin M, Gordon K, Bushnell D, Pinto L, Viswanathan H. Qualitative Assessment of the Experience of Pain in Patients with Moderate to Severe Plaque Psoriasis. ISPOR, Montreal, 2014.
Martin M, Gordon K, Bushnell D, Pinto L, Chau D, Viswanathan H. Qualitative Assessment of the Experience of Pain in Patients with Moderate to Severe Plaque Psoriasis. EADV, Amsterdam, 2014.
Mease PJ, Genovese MC, Mutebi A, Wilson H, Revicki DA, Erondu N, Nirula A, Feng JY, Viswanathan HN. Reliability and Construct Validity of the Psoriasis Symptom Inventory in Subjects with Psoriatic Arthritis. Presented at ACR/ARHP Annual Meeting; Boston, MA, USA, 2014.
Bushnell DM, Marin ML, McCarrier KP, Chiou CF, Ortmeier B. Comparison of a 24-Hour and 7-Day Version of a Patient Reported Outcome Measure for Psoriasis Symptom Severity. Presented at ISPOR, Washington, DC, 2012.
Martin M, Chen T, Chau D, Viswanathan H. Qualitative Interviews with Psoriasis Patients Evaluating Paper to Electronic Migration of the Psoriasis Symptom Inventory (PSI). Presented at ISOQOL, Budapest, 2012.
Revicki D, Jin Y, Chau D, Viswanathan H. Reliability and Validity of the Psoriasis Symptom Inventory in Patients with Moderate to Severe Psoriasis. ISOQOL, Budapest, 2012.
Martin ML, McCarrier K, Bushnell DM, Gordon K, Chiou C, Huang X, Ortmeier B, Kricorian G Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure. AAD, San Diego, 2012.
Martin ML, McCarrier K, Bushnell DM, Gordon K, Huang X, Chiou C, Ortmeier B, Kricorian G. Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure. EADV, Lisbon, 2011